Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Repeated-dosing, Multiple Ascending Dose Trial to Evaluate the Safety and Tolerability of a Novel PCSK-9 Anti-body, IBI306, in Chinese Patients With Hypercholesterolemia

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Repeated-dosing, Multiple Ascending Dose Trial to Evaluate the Safety and Tolerability of a Novel PCSK-9 Anti-body, IBI306, in Chinese Patients With Hypercholesterolemia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tafolecimab (Primary)
  • Indications Hypercholesterolaemia; Hyperlipidaemia
  • Focus Adverse reactions
  • Sponsors Innovent Biologics

Most Recent Events

  • 01 Sep 2020 Results assessing safety and efficacy from two studies: phase 1 single ascending does study (n=58) and phase 2 multiple ascending dose study presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology
  • 30 Aug 2020 According to an Innovent Biologics media release, Prof. Yong Huo, the director of the Department of Cardiology at Peking University First Hospital is the leading PI of this study (CIBI306B101).
  • 30 Aug 2020 According to an Innovent Biologics media release, this study results were successfully presented in the 2020 European Society of Cardiology (ESC) annual conference (August 29 to September 1, Central European Summer Time) as e-Poster.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top